The future of cancer
diagnostics is now

WE IDENTIFY GENETIC CAUSES OF CANCER

The most powerful
biomarker discovery platform

GEMMAai™

GEnoMic Marker Analyzer

AI-Powered platform for matching patients with right treatment

GEMMAai for clinical trial enrolment – available *
GEMMAai for companion diagnostics development – available *
GEMMAai for patients coming soon – pipeline *

TUMOR
TYPE

TUMOR GENOMES

TARGETED THERAPY

DISCOVERY

PROTOTYPE ASSAY

ANALITYCAL VALIDATION

CLINICAL VALIDATION

REGULATORY APPROVAL

UPCOMING
MILESTONES

BREAST

2152

CDK4/6i
Ant-HER2
PARPi
mTORi
PIK3i

Title

65%

Title

65%

Title

45%

Title

15%

Title

15%

2 analytically validated diagnostic tools in Q1 2021

OVARIAN

512

Carboplatin / PARPi

Title

65%

FDA breakthrough device submission Q2 2021

FASETM

GENOMIC FEATURE DATABASE

YOUR inhibitor

Discovery and validation

AI-POWERED
STRATIFICATION DIAGNOSTIC TOOL

Learn more

* For Research Use Only. Not for use in diagnostic procedures.

TUMOR TYPE: OVARIAN

WGS DATA

512

TARGETTED THERAPY

Carboplatin / PARPi

65%

UPCOMING MILESTONES

FDA breakthrough device in Q3 2021

TUMOR TYPE: BREAST

WGS DATA

2152

TARGETTED THERAPY

PARPi

65%

CDK4/6i

25%

Ant-HER2

45%

mTORi

15%

PIK3i

15%

UPCOMING MILESTONES

2 analytically validated diagnostic tools in Q1 2021

TUMOR TYPE: LUNG

WGS DATA

1852

TARGETTED THERAPY

PARPi

10%

immunotherapy

10%

UPCOMING MILESTONES

2 prototype assays in Q3 2021

FUSETM

WGS DATA

GENOMIC FEATURE DATABASE

TARGETTED THERAPY

YOUR inhibitor

DISCOVERY AND VALIDATION

AI-POWERED STRATIFICATION DIAGNOSTIC TOOL

News

14 maja 2021 in News

BiO€QUITY Europe on 17-19 May 2021

MNM Diagnostics has developed a unique AI-powered platform allowing for the rapid development of genome-based biomarkers providing an accurate prediction of the treatment outcomes for cancer patients. To date, we…
Read More
9 kwietnia 2021 in News

Certificate of Approval ISO 9001:2015

MNM Diagnostics received Certificate of Approval to the standards ISO 9001:2015, which means we meet requirements of the management standards in the organization in the field of : "Banking and…
Read More
13 stycznia 2021 in News

The success of Polish scientists. Research on COVID-19 has been recognized as one of the most remarkable discoveries in 2020 by Nature

Research indicating the genetic background of the severe illness in COVID-19 cases, co-authored by Dr. Paweł Zawadzki from MNM Diagnostics and the Polish Biobanking Center, was among the most remarkable…
Read More
13 stycznia 2021 in News

ICZMP in Łódź: whole-genome diagnostics for patients with breast and ovarian cancer

Patients of the Polish Mother's Memorial Hospital Research Institute in Łódź have gained access to a cancer diagnosis method based on tumor DNA analysis. ICZMP signed an agreement on this…
Read More

Our publications

Partners

Masz pytania lub wątpliwości?

Napisz do nas

    Wyrażam zgodę na newsletter

    Zapoznałem się i akceptuję politykę prywatności oraz klauzulę informacyjną
    polityka prywatności | klauzula informacyjna

    W pośpiechu?

    Pobierz ulotkę



      jestem pacjentemjestem lekarzemjestem studentem
      Wyrażam zgodę na newsletter
      Zapoznałem się i akceptuję politykę prywatności oraz klauzulę informacyjną
      polityka prywatności
      klauzula informacyjna